Similarly, in B16F10 melanoma, the inhibition of NLRP3 reduced tumor growth and synergized with checkpoint blockade therapy, suggesting that inflammasome-derived IL-1β promotes tumorigenesis [138]. The gene discussed is IL1B; the disease is melanoma.